# US 2025/0145588 A1 · Crystal form of tavapadon, and preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145588 A1
- Document ID: US20250145588A1
- Status: Published application
- Kind: A1
- Application number: 18/832,506
- Filed: 2023-01-18
- Published: 2025-05-08
- Earliest claimed: 2022-01-29
- Assignees: Crystal Pharmaceutical (Suzhou) Co., Ltd.
- Applicants: Crystal Pharmaceutical (Suzhou) Co., Ltd.
- Inventors: Haiyan QIN; Jiaming SHI
- Web page: https://patentgrep.com/patent/US20250145588A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A novel crystalline form of Tavapadon (hereinafter referred to as “Compound I”) and its preparation method, pharmaceutical compositions containing this crystalline form, and its use in the preparation of dopamine D1/D5 receptor agonist drugs and in the treatment of Parkinson's disease. The crystalline form of Compound I provided by the present disclosure has one or more improved properties compared to prior arts, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.

## Claims

### Claim at position 1

1-5. (canceled)

### Claim 6

A crystalline form of Compound I
wherein the X-ray powder diffraction pattern comprises characteristic peaks at 2theta values of 7.8°±0.2°, 15.1°±0.2° and 17.0°±0.2° using Cu-Kα radiation.

### Claim 7 (depends on 6)

The crystalline form according to claim 6, wherein the X-ray powder diffraction pattern comprises at least one characteristic peak at 2theta values of 18.7°±0.2°, 23.2°±0.2° and 26.0°±0.2° using Cu-Kα radiation.

### Claim 8 (depends on 6)

The crystalline form according to claim 6, wherein the X-ray powder diffraction pattern comprises at least one characteristic peak at 2theta values of 23.8°±0.2° and 24.4°±0.2° using Cu-Kα radiation.

### Claim 9 (depends on 7)

The crystalline form according to claim 7, wherein the X-ray powder diffraction pattern comprises at least one characteristic peak at 2theta values of 23.8°±0.2° and 24.4°±0.2° using Cu-Kα radiation.

### Claim 10 (depends on 6)

The crystalline form according to claim 6, wherein the X-ray powder diffraction pattern is substantially as shown in FIG. 4.

### Claim 11 (depends on 6)

A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of the crystalline form according to claim 6, and pharmaceutically acceptable excipients.

### Claim 12 (depends on 6)

A method of preparing drugs of dopamine D1/D5 receptor agonists, comprising using the crystalline form according to claim 6.

### Claim 13 (depends on 6)

A method of preparing drugs for treating Parkinson's disease, comprising using the crystalline form according to claim 6.
